KR20230057824A - A rapid preparation method for a peracetic acid solution provided as single formulation - Google Patents
A rapid preparation method for a peracetic acid solution provided as single formulation Download PDFInfo
- Publication number
- KR20230057824A KR20230057824A KR1020210142044A KR20210142044A KR20230057824A KR 20230057824 A KR20230057824 A KR 20230057824A KR 1020210142044 A KR1020210142044 A KR 1020210142044A KR 20210142044 A KR20210142044 A KR 20210142044A KR 20230057824 A KR20230057824 A KR 20230057824A
- Authority
- KR
- South Korea
- Prior art keywords
- peracetic acid
- acid solution
- acid
- present
- weight
- Prior art date
Links
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title abstract description 27
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 45
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000004327 boric acid Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 14
- 230000032683 aging Effects 0.000 claims description 20
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000008213 purified water Substances 0.000 abstract description 15
- 239000000645 desinfectant Substances 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 11
- 239000003054 catalyst Substances 0.000 abstract description 8
- 238000007865 diluting Methods 0.000 abstract description 4
- 238000011109 contamination Methods 0.000 abstract description 3
- 238000009826 distribution Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000013049 sediment Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 34
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 101100376153 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TY2A-F gene Proteins 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000001223 reverse osmosis Methods 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003377 acid catalyst Substances 0.000 description 5
- 238000013094 purity test Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
본 발명은 과아세트산 용액의 신속 제조방법에 관한 것으로, 구체적으로 아세트산 무수물, 과산화수소, 물, 안정화제 및 붕산을 단시간 반응시키는 단계를 포함하는 과아세트산 용액의 제조방법, 및 이로부터 제조된 과아세트산 용액에 관한 것이다.The present invention relates to a method for rapidly preparing a peracetic acid solution, and specifically, a method for preparing a peracetic acid solution comprising reacting acetic anhydride, hydrogen peroxide, water, a stabilizer and boric acid in a short time, and a peracetic acid solution prepared therefrom It is about.
최근 노령 인구와 만성질환자 증가, 항암제 및 면역억제제 사용으로 인한 면역부전환자의 증가 등으로 침습적 의료 행위에 이용되는 의료기구의 살균/소독이 매우 중요하게 다루어지고 있다. 의료기구의 살균/소독이 제대로 되지 못할 경우 병원균 감염으로 인해 환자의 건강을 위협할 수 있으며, 이로 인해 입원 기간 연장, 의료비용 증가 등으로 사회적 손실이 발생할 수 있다. 현재 국내에서 의료기구의 살균소독제로 시판 중인 제품의 성분은 과아세트산, 산화에틸렌, 시트르산수화물, 염화벤잘코늄, 클로르헥시딘글루콘산염 등으로 다양하다.Recently, sterilization/disinfection of medical devices used in invasive medical practices has become very important due to the increase in the elderly population, chronic disease patients, and the increase in immunocompromised patients due to the use of anticancer drugs and immunosuppressants. Failure to properly sterilize/disinfect medical devices can threaten the health of patients due to infection with pathogens, which can lead to social losses such as prolonged hospitalization and increased medical costs. The ingredients of products currently marketed as disinfectants for medical instruments in Korea are various, such as peracetic acid, ethylene oxide, citric acid hydrate, benzalkonium chloride, and chlorhexidine gluconate.
이 중 과아세트산 용액은 과아세트산을 함유하는 평형 용액을 말하며, 일반 세균뿐만 아니라 각종 진균, 항산성균, 포자에 대한 살균 효과를 가지고, 또한 단순포진 바이러스, 아데노바이러스, 소아마비 바이러스 등을 불활성화하는 것으로 알려져 있다. 따라서 과아세트산 용액은 의료기구의 살균소독 용도로 매우 유용하게 사용되고 있다. Among them, the peracetic acid solution refers to a balanced solution containing peracetic acid, and has a bactericidal effect on various fungi, acid-fast bacteria, and spores as well as general bacteria, and is known to inactivate herpes simplex virus, adenovirus, polio virus, etc. there is. Therefore, the peracetic acid solution is very useful for sterilization and disinfection of medical instruments.
대한민국 등록특허 제10-0426937호는 과아세트산 용액의 실용액이 적어도 7 일간 유지되는 조성물을 개시하고 있는데, 종래 제제의 실용액 (과아세트산 약 2 % 함유)의 셀프 라이프가 1 일 내지 3 일 수준인 점을 개선하기 위해 과아세트산을 함유하는 제1 시약과 인산염 및 비이온 계면활성제를 함유하는 제2 시약을 별도로 제조하고, 사용 시 상기 제1 시약과 제2 시약을 혼합하여 사용하는 형태의 과아세트산 용액을 개시하고 있다. 또한, 대한민국 등록특허 제10-0876684호는 과아세트산 및 아세틸살리실산을 함유하는 살균 조성물을 개시하고 있는데, 초산, 과산화수소, 과초산을 함유하는 제1 용액 및 아세틸살리실산을 함유하는 제2 용액을 혼합하여 사용하는 형태로서, 정제수로 희석될 경우에도 3 주 이상 장시간 보존하며 사용될 수 있음을 개시하고 있다. 그러나 이와 같이 살균 조성물을 2 종의 용액으로 구성하여 제공할 경우, 제조 공정이 매우 복잡해지고 제조 비용이 증가할 뿐만 아니라, 실용액 제조 시 두 용액을 혼합하는 과정을 반드시 거쳐야하므로 사용이 불편하며, 혼합 과정에서 제품이 오염될 위험도가 증가하여 위생 상 불리하다는 단점을 가진다.Korean Patent Registration No. 10-0426937 discloses a composition in which a practical solution of a peracetic acid solution is maintained for at least 7 days, and the self-life of a practical solution (containing about 2% peracetic acid) of a conventional formulation is 1 to 3 days. In order to improve the phosphorus point, a first reagent containing peracetic acid and a second reagent containing a phosphate and a nonionic surfactant are separately prepared, and the first reagent and the second reagent are mixed and used when used. An acetic acid solution is disclosed. In addition, Korean Patent Registration No. 10-0876684 discloses a sterilization composition containing peracetic acid and acetylsalicylic acid. A first solution containing acetic acid, hydrogen peroxide, and peracetic acid and a second solution containing acetylsalicylic acid are mixed to As a form of use, it is disclosed that it can be used while preserving for a long time of 3 weeks or more even when diluted with purified water. However, when the sterilization composition is provided as composed of two types of solutions, the manufacturing process is very complicated and the manufacturing cost increases, and the process of mixing the two solutions must be performed during the preparation of the practical solution, so it is inconvenient to use, The risk of contamination of the product increases during the mixing process, which is disadvantageous in terms of hygiene.
한편, 종래 단일제 형태로 제공되는 살균 조성물로서 대한민국 등록특허 제10-0363896호에서는 과초산, 인산 등을 포함하는 의료기기 세척제를 개시하고, 대한민국 등록특허 제10-0597092호에서는 과초산, 유기산 (시트릭산, 말릭산, 글리콜릭산, 옥살산, 숙신산, 포름산) 등을 포함하는 과초산 수용액을 개시하고 있으나, 이들 모두 반응 후 최소 3 일 내지 10 일 간의 숙성 시간을 필요로 하여 제조 시간이 오래 걸린다는 한계가 있었다. 또한, 종래 살균 조성물은 좋은 품질의 정제수, 역삼투압수 등의 특정 용매와 혼합하여 사용하지 않을 경우 염을 형성하는 문제가 있어 사용에 불편함이 있었다.On the other hand, as a conventional disinfectant composition provided in the form of a single agent, Korean Patent Registration No. 10-0363896 discloses a medical device cleaner containing peracetic acid, phosphoric acid, etc., and Korean Patent Registration No. 10-0597092 discloses peracetic acid, organic acid (sheet Although an aqueous solution of peracetic acid including lactic acid, malic acid, glycolic acid, oxalic acid, succinic acid, formic acid) is disclosed, all of them require a minimum aging time of 3 to 10 days after reaction, so the manufacturing time is long. there was In addition, conventional sterilization compositions have a problem of forming salts when not mixed with a specific solvent such as good quality purified water or reverse osmosis water, which is inconvenient for use.
본 발명의 하나의 목적은, (a) 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계; (b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및 (c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법을 제공하는 것이다.One object of the present invention, (a) mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide and water; (b) adding and mixing a stabilizer to the mixture of step (a); and (c) mixing 0.5% to 5% by weight of boric acid with the mixture of step (b) and reacting at 30 ° C. to 50 ° C. for 2 to 4 hours. It is to provide a manufacturing method.
본 발명의 다른 하나의 목적은, 상기 제조방법으로 제조된 과아세트산 용액을 단일제 형태로 제공하는 것이다.Another object of the present invention is to provide a peracetic acid solution prepared by the above preparation method in the form of a single agent.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.A detailed description of this is as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, (a) 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계; (b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및 (c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법이다.One aspect of the present invention for achieving the above object is, (a) mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide and water; (b) adding and mixing a stabilizer to the mixture of step (a); and (c) mixing 0.5% to 5% by weight of boric acid with the mixture of step (b) and reacting at 30 ° C. to 50 ° C. for 2 to 4 hours. is a manufacturing method.
본 발명에서 용어 "과아세트산 용액 (peracetic acid solution)"은 과아세트산을 포함하는 용액을 지칭하며, 과초산 용액과 같은 의미로 사용된다. 과아세트산 용액은 세균, 진균, 박테리아 등에 항균활성을 가지므로 의료기구의 소독세정제로서 매우 유용하게 사용될 수 있다. 특히, 본 발명의 제조방법에 의해 제조된 과아세트산 용액은 종래 기술과 달리 단일제로 제공되어 제조 공정이 간편하고 제조 비용이 저렴하며, 유통이 편리하고, 사용이 용이하며, 실용액 제조에 따른 오염의 위험성이 상대적으로 적다. In the present invention, the term "peracetic acid solution" refers to a solution containing peracetic acid, and is used in the same sense as peracetic acid solution. Since the peracetic acid solution has antibacterial activity against bacteria, fungi, and bacteria, it can be used very usefully as a disinfectant and cleaner for medical devices. In particular, the peracetic acid solution prepared by the production method of the present invention is provided as a single agent unlike the prior art, so the production process is simple, the production cost is low, the distribution is convenient, and the use is easy. risk is relatively small.
상기 제조방법에서 (a) 단계는 아세트산 무수물 37 중량% 내지 41 중량%, 과산화수소 10 중량% 내지 12 중량% 및 물을 혼합하는 단계이다. 통상 과아세트산을 제조하기 위해 아세트산 (CH3COOH)과 과산화수소 (H2O2)를 반응시키는데, 본 발명에서 출발물질로 채택한 아세트산 무수물 ((CH3CO)2O)은 생성물에서 아세트산 대비 수분 함량이 상대적으로 낮다는 점에서 차이를 갖는다. 본 발명에서는 구체적인 실험을 통하여 제조 시간을 단축시킬 수 있는 각 성분의 최적 함량 및 최적 공정을 도출하였다. In the above preparation method, step (a) is a step of mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide, and water. In general, acetic acid (CH 3 COOH) and hydrogen peroxide (H 2 O 2 ) are reacted to produce peracetic acid. In the present invention, acetic anhydride ((CH 3 CO) 2 O) used as a starting material is It differs in that it is relatively low. In the present invention, the optimal content and optimal process of each component that can shorten the manufacturing time were derived through specific experiments.
본 발명에서 물은 정제수, 역삼투압수 또는 일반 수돗물일 수 있으나, 이에 제한되지 않는다. 후술하는 바와 같이, 본 발명의 과아세트산 용액은 염 형성 문제가 적어 사용상 편리성을 갖는다.In the present invention, water may be purified water, reverse osmosis water, or general tap water, but is not limited thereto. As will be described later, the peracetic acid solution of the present invention has little salt formation problem and is convenient to use.
단계 (b)는 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계이다. 상기 안정화제는 1-히드록시에탄-1,1-디포스폰산, 1-옥탄설폰산나트륨, {[(카르복시메틸)이미노]비스(에틸렌니트릴로)}테트라아세트산, EDTA 소듐염 또는 이들의 조합일 수 있으나 이에 제한되는 것은 아니다. 과아세트산 수용액은 평형 상태로 존재하므로 본 발명에서 안정화제는 과아세트산 용액의 평형 상태를 안정화시킬 수 있는 임의의 물질을 적절히 선택하여 사용할 수 있다. 상기 안정화제의 함량은 과아세트산 용액의 안정성, 부식성 등을 고려하여 적절히 조절될 수 있으며, 예컨대 0.1 중량% 내지 3 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다. Step (b) is a step of adding and mixing a stabilizer to the mixture of step (a). The stabilizer is 1-hydroxyethane-1,1-diphosphonic acid, sodium 1-octanesulfonate, {[(carboxymethyl)imino]bis(ethylenenitrilo)}tetraacetic acid, EDTA sodium salt or any of these It may be a combination, but is not limited thereto. Since the aqueous solution of peracetic acid exists in an equilibrium state, any material capable of stabilizing the equilibrium state of the peracetic acid solution may be appropriately selected and used as the stabilizer in the present invention. The content of the stabilizer may be appropriately adjusted in consideration of stability, corrosiveness, etc. of the peracetic acid solution, and may include, for example, 0.1% to 3% by weight, but is not limited thereto.
단계 (c)는 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계이다. Step (c) is a step of mixing 0.5% by weight to 5% by weight of boric acid with the mixture of step (b) and reacting at 30 ℃ to 50 ℃ for 2 hours to 4 hours.
본 발명의 제조방법은 특히 과아세트산의 평형반응을 촉진시키기 위한 산 촉매로 붕산을 채택한 것을 기술적 특징으로 한다. 종래 인산, 황산, 또는 시트릭산, 글리콜릭산, 옥살산, 숙신산, 포름산과 같은 유기산을 산 촉매로 사용하여 과아세트산 수용액을 제조하는 방법은 공지된 바 있으나, 본 발명과 같이 붕산을 사용한 예는 전혀 알려진 바 없다. The manufacturing method of the present invention is particularly characterized by the adoption of boric acid as an acid catalyst for accelerating the equilibrium reaction of peracetic acid. Conventionally, a method for preparing an aqueous solution of peracetic acid using phosphoric acid, sulfuric acid, or an organic acid such as citric acid, glycolic acid, oxalic acid, succinic acid, or formic acid as an acid catalyst has been known, but no example using boric acid as in the present invention is known. no bar
병원 및 의료기관에서 살균소독제로 과아세트산 제제를 사용할 경우, 일반적으로 정제수 또는 역삼투압수를 사용하지만, 편의상 혹은 비용상의 문제로 좋은 품질의 정제수, 역삼투압수 등을 사용하지 않고 수돗물, 또는 기준에 미달하는 정제수, 역삼투압수 등에 희석하여 사용하는 경우가 빈번히 발생한다. 이와 같이 과아세트산 제제 (기존 제제의 경우, 인산을 함유하는 제형이 다수)를 수돗물 등에 희석하여 사용할 경우, 염을 형성하여 침전물이 형성되고 소독기 장비에 펌프, 파이프, 용매 흐름관에 염이 침적되는 문제가 많이 지적되어왔다. 그러나 붕산을 사용한 본 발명의 과아세트산 용액은 이러한 문제점을 전혀 나타내지 않는다. When using peracetic acid as a disinfectant in hospitals and medical institutions, purified water or reverse osmosis water is generally used, but for convenience or cost reasons, good quality purified water or reverse osmosis water is not used and tap water or less than the standard It is frequently used after diluting with purified water or reverse osmosis water. In this way, when a peracetic acid formulation (many formulations containing phosphoric acid in the case of existing formulations) are diluted with tap water and used, a precipitate is formed by forming a salt, and the salt is deposited in the pump, pipe, and solvent flow pipe in the disinfector equipment. Many problems have been pointed out. However, the peracetic acid solution of the present invention using boric acid does not present these problems at all.
구체적으로 상기 단계 (c)는 35 ℃ 내지 45 ℃에서 3 시간 동안 반응시키는 것일 수 있으나, 이에 제한되는 것은 아니다. 상기 명시된 온도, 시간 조건에서 다소 차이가 나더라도 본 발명과 동등한 제조 시간 단축 효과를 나타내는 한 모두 균등 범위로서 본 발명의 범주에 포함될 수 있음은 당업자에게 자명하다.Specifically, the step (c) may be a reaction for 3 hours at 35 ℃ to 45 ℃, but is not limited thereto. It is obvious to those skilled in the art that even if there is a slight difference in the above-specified temperature and time conditions, all of them can be included in the scope of the present invention as equivalent ranges as long as they exhibit the effect of reducing the manufacturing time equivalent to that of the present invention.
한편, 이에 제한되는 것은 아니나 본 발명의 일 실시양태로서, 상기 (a) 단계의 아세트산 무수물은 39 중량%이고, 과산화수소수는 11.5 중량%이며, 상기 (c) 단계의 붕산은 2 중량%이고, 30 ℃ 내지 40 ℃에서 반응시키는 것일 수 있다.On the other hand, but is not limited thereto, as an embodiment of the present invention, the acetic anhydride in step (a) is 39% by weight, the hydrogen peroxide solution is 11.5% by weight, the boric acid in step (c) is 2% by weight, It may be to react at 30 ℃ to 40 ℃.
본 발명의 다른 일 실시양태로서, 상기 (a) 단계의 아세트산 무수물은 37 중량% 내지 41 중량%이고, 과산화수소수는 11.5 중량%이며, 상기 (c) 단계의 붕산은 2 중량%이고, 40 ℃ 내지 50 ℃에서 반응시키는 것일 수 있다.As another embodiment of the present invention, the acetic anhydride in step (a) is 37% to 41% by weight, the hydrogen peroxide is 11.5% by weight, the boric acid in step (c) is 2% by weight, and 40 ° C. It may be to react at 50 ℃.
본 발명의 제조방법은 추가적으로, (d) 상기 (c) 단계의 반응물을 상온에서 숙성시키는 단계를 포함하는 것일 수 있다. 상기 숙성시키는 단계는 바람직한 과아세트산 및 과산화수소 ?t량을 달성하기 위해 제조방법의 일 단계로서 포함될 수 있으며, 예컨대 1 시간 내지 3 시간일 수 있으나, 이에 제한되는 것은 아니다.The manufacturing method of the present invention may additionally include the step of (d) aging the reactant of step (c) at room temperature. The aging step may be included as one step of the manufacturing method in order to achieve a desired amount of peracetic acid and hydrogen peroxide, for example, 1 hour to 3 hours, but is not limited thereto.
본 발명의 구체적인 실시예에서는 산 촉매를 포함하지 않는 군 (기존 당사 제형, F005), 산 촉매로서 인산 (F002, F003) 또는 붕산 (F004, F006, F006-1, F007, F008)을 포함하는 군에 대하여 다양한 조건에서 실험을 수행하였다. 그 결과, 산 촉매로서 붕산을 채택할 경우 상온에서도 과초산 6 % 합성기간이 절반 수준으로 감소되는 것을 확인하였으며 (표 1, 도 1 및 도 2), 특히 온도를 35 ℃ 내지 45 ℃로 올려서 반응시킨 경우 최소 3 시간의 반응만으로 과초산 6 % 합성이 가능함을 확인하였다 (표 2, 표 3 및 도 3 내지 도 6). 따라서 본 발명의 제조방법은 매우 짧은 시간에 단일제로서 제공되는 과아세트산 용액을 제조할 수 있어, 종래 제조방법에 비해 현저히 우수한 제조 효율성을 갖는다. In a specific embodiment of the present invention, a group containing no acid catalyst (our existing formulation, F005), a group containing phosphoric acid (F002, F003) or boric acid (F004, F006, F006-1, F007, F008) as an acid catalyst Experiments were conducted under various conditions. As a result, when boric acid was used as an acid catalyst, it was confirmed that the synthesis period of 6% peracetic acid was reduced by half even at room temperature (Table 1, Fig. 1 and Fig. 2). In this case, it was confirmed that 6% peracetic acid could be synthesized with only a reaction of at least 3 hours (Table 2, Table 3 and FIGS. 3 to 6). Therefore, the manufacturing method of the present invention can produce a peracetic acid solution provided as a single agent in a very short time, and has significantly superior manufacturing efficiency compared to conventional manufacturing methods.
상기 목적을 달성하기 위한 본 발명의 다른 하나의 양태는 상기 제조방법으로 제조된, 단일제로 제공되는 과아세트산 용액이다. 상기 과아세트산 용액은 과아세트산을 5.4 중량% 내지 8 중량%로 함유하고 과산화수소를 10 중량% 이하로 함유하는 것일 수 있다. 본 발명의 과아세트산 용액은 상기 설명한 바와 같다.Another aspect of the present invention for achieving the above object is a peracetic acid solution prepared by the above production method and provided as a single agent. The peracetic acid solution may contain 5.4% to 8% by weight of peracetic acid and 10% by weight or less of hydrogen peroxide. The peracetic acid solution of the present invention is as described above.
본 발명의 과아세트산 용액은 내시경 등 의료기구의 세척 사용시 물에 희석하여 사용될 수 있다.The peracetic acid solution of the present invention may be diluted in water and used when cleaning medical instruments such as an endoscope.
본 발명의 과아세트산 용액의 제조방법은 종래 제조방법에 비해 제조시간을 현저히 단축시킬 수 있고, 제조 공정이 간편하고 제조 비용이 저렴하다. 뿐만 아니라 1 제, 2 제를 혼합하고 다시 정제수로 희석하여 사용하는 기존 제품과 달리, 본 발명의 과아세트산 용액은 단일제로서 유통이 편리하고, 1 제에 정제수를 희석하여 바로 사용이 가능한 편리성을 제공하며, 장기 보존시에도 침전물의 발생이 없고 실용액 제조에 따른 오염의 위험성이 적어 의료기기의 소독살균제로서 매우 유용하게 사용될 수 있다. 또한, 촉매로 붕산을 사용함으로써 염 형성 문제가 적어 소독살균제로서 이용에 매우 편리하다.The preparation method of the peracetic acid solution of the present invention can significantly reduce the preparation time compared to the conventional preparation method, and the manufacturing process is simple and the manufacturing cost is low. In addition, unlike existing products in which agents 1 and 2 are mixed and then diluted with purified water, the peracetic acid solution of the present invention is a single agent, which is convenient to distribute and can be used immediately by diluting the first agent with purified water. In addition, there is no precipitate even during long-term storage and the risk of contamination due to the preparation of practical solution is low, so it can be used very usefully as a disinfectant for medical devices. In addition, since boric acid is used as a catalyst, the problem of salt formation is small, so it is very convenient to use as a disinfectant.
도 1은 상온에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 2는 상온에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 3은 35 ℃에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 4는 35 ℃에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 5는 45 ℃에서 제조된 실시예 제제들의 과산화수소 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 6은 45 ℃에서 제조된 실시예 제제들의 과아세트산 함량을 숙성 시간에 따라 측정한 결과를 나타낸 것이다.
도 7은 기존 시판 제형과 F002, F006 및 F006-1 제형의 염 석출 시험 결과를 나타낸 것이다.Figure 1 shows the results of measuring the hydrogen peroxide content of the example formulations prepared at room temperature according to the aging time.
Figure 2 shows the results of measuring the peracetic acid content of the example formulations prepared at room temperature according to the aging time.
Figure 3 shows the results of measuring the hydrogen peroxide content of the example formulations prepared at 35 ℃ according to the aging time.
Figure 4 shows the results of measuring the peracetic acid content of the example formulations prepared at 35 ℃ according to the aging time.
Figure 5 shows the results of measuring the hydrogen peroxide content of the example formulations prepared at 45 ℃ according to the aging time.
Figure 6 shows the results of measuring the peracetic acid content of the example formulations prepared at 45 ℃ according to the aging time.
Figure 7 shows the results of salt precipitation tests of existing commercially available formulations and F002, F006 and F006-1 formulations.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, but the scope of the present invention is not limited by these examples.
실시예: 과아세트산 제제의 제조방법Example: Manufacturing method of peracetic acid preparation
실시예 1 (기존 당사 제형, F005)Example 1 (our existing formulation, F005)
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w; 최종 함량 약 0.11 ~ 0.14 %)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.31 ~ 43% (w/w) of acetic anhydride, 33 ~ 39% (w/w; final content of about 0.11 ~ 0.14%) of 35% hydrogen peroxide solution and purified water are mixed, and 1-hydroxyethane- 1,1-diphosphonic acid was added and mixed. After the 3-hour mixing process, in some cases, after aging at room temperature, the quality test was conducted.
실시예 2 (F002, F003)Example 2 (F002, F003)
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고 pH를 조절하기 위해 인산을 1 ~ 3 %까지 투입하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.31 ~ 43% (w/w) of acetic anhydride, 33 ~ 39% (w/w) of 35% hydrogen peroxide solution and purified water were mixed, and 1-hydroxyethane-1,1-diphosphonic acid was used as a stabilizer. After mixing, phosphoric acid was added in an amount of 1 to 3% to adjust the pH. After the 3-hour mixing process, in some cases, after aging at room temperature, the quality test was conducted.
실시예 3 (F004, F006, F007, F008)Example 3 (F004, F006, F007, F008)
기존 과아세트산 제품들의 경우 대부분 인산을 함유하고 있었으나, 이 경우 수돗물 내 양이온과 반응하여 세척기 내 흰색의 염을 형성하는 문제점이 발생된다는 보고가 있었다. 따라서 실시예 3에서는 인산을 유사한 무기산의 한 종류인 붕산으로 변경하였다. 붕산의 경우 그 자체로 소독력과 방부력을 가지고 있으며, 인산에 비해 pH가 높아 상대적으로 부식력이 약한 물질로 알려져 있다.In the case of existing peracetic acid products, most of them contained phosphoric acid, but in this case, there was a report that a white salt was formed in the washing machine by reacting with cations in tap water. Therefore, in Example 3, phosphoric acid was changed to boric acid, which is a kind of similar inorganic acid. In the case of boric acid, it has disinfection and antiseptic power itself, and is known as a substance with relatively weak corrosive power due to its higher pH than phosphoric acid.
아세트산무수물 31 ~ 43 % (w/w), 과산화수소수 35 % 액 33 ~ 39 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고, pH를 조절하기 위해 붕산을 1 ~ 5 %까지 투입하였다. 3 시간 혼합 공정이 끝난 후, 경우에 따라 상온에서 숙성시킨 뒤 품질 시험을 진행하였다.31 ~ 43% (w/w) of acetic anhydride, 33 ~ 39% (w/w) of 35% hydrogen peroxide solution and purified water were mixed, and 1-hydroxyethane-1,1-diphosphonic acid was used as a stabilizer. After mixing, 1 to 5% of boric acid was added to adjust the pH. After the 3-hour mixing process, in some cases, after aging at room temperature, the quality test was conducted.
실시예 4 (F006-1)Example 4 (F006-1)
실시예 4는 기존 F006에서 붕산 함량을 추가적으로 조정한 것이다. 아세트산무수물 41 % (w/w), 과산화수소수 35 % 액 33 % (w/w)와 정제수를 넣어 혼합한 뒤, 안정화제로 1-히드록시에탄-1,1-디포스폰산을 넣어 혼합하고 pH를 조절하기 위해 인산을 0.5 %로 투입하였다.Example 4 is to further adjust the boric acid content in the existing F006. Add 41% (w/w) of acetic anhydride, 33% (w/w) of 35% hydrogen peroxide solution and purified water, mix, add 1-hydroxyethane-1,1-diphosphonic acid as a stabilizer, mix, and Phosphoric acid was added at 0.5% to control.
실험예: 제조공정 별 비교실험Experimental Example: Comparative experiment by manufacturing process
상기 실시예에 해당하는 각각의 과아세트산 제제 (기존 당사 제형 및 F002 내지 F008)를 상온 (20 ~ 25 ℃), 35 ℃ 또는 45 ℃에서 3 시간 반응시킨 뒤, 필요할 경우 상온에서 숙성시켰다. 그 다음, 적정법을 이용하여 과산화수소수 순도시험 및 과아세트산 함량 분석을 진행하였다. Each of the peracetic acid formulations (our existing formulations and F002 to F008) corresponding to the above examples were reacted at room temperature (20 to 25 ° C), 35 ° C or 45 ° C for 3 hours, and then aged at room temperature if necessary. Then, a hydrogen peroxide water purity test and peracetic acid content analysis were performed using a titration method.
실험예 1. 과아세트산 6 %, 상온 공정Experimental Example 1. Peracetic acid 6%, room temperature process
[표 1][Table 1]
F : Fail, P : Pass, NT : Not testedF: Fail, P: Pass, NT: Not tested
과아세트산 제제에 있어서 과아세트산의 농도가 너무 낮으면 충분한 살균·소독 효과를 얻을 수 없고, 과산화수소 함량이 너무 높으면 인체에 해로운 영향을 주므로, 실시예로부터 제조된 제제들의 과산화수소 및 과아세트산 함량을 측정하고자 하였다. In the peracetic acid preparation, if the concentration of peracetic acid is too low, sufficient sterilization and disinfection effects cannot be obtained, and if the hydrogen peroxide content is too high, it has a harmful effect on the human body. did
먼저, 상온 공정 조건에서 과산화수소수의 순도 시험을 진행한 결과, 기존 당사 제형의 경우 약 10 일, F002는 7 일, F003, F004와 F005의 경우 4 일, F006은 2 일, F007과 F008은 1 일 경과 후 의약품 품질관리 기준에 적합함을 확인하였다 (표 1 및 도 1). First, as a result of conducting a purity test of hydrogen peroxide water under room temperature process conditions, about 10 days for our existing formulation, 7 days for F002, 4 days for F003, F004 and F005, 2 days for F006, and 1 day for F007 and F008. After one day, it was confirmed that the drug quality control standards were met (Table 1 and FIG. 1).
순도시험 후 과아세트산 함량 시험 결과, 기존 당사 제형과 F002, F006는 6 % 함량 기준을 만족하기 위해 반응 후 추가적으로 4 일의 숙성시간이 필요하였으며, F007은 2 일, F008은 3 일의 숙성시간이 필요한 것으로 확인 되었다 (표 1 및 도 2). F003, F004, F005의 경우 순도 적합기한이 4 일 가량 필요하여, 과아세트산 함량 실험에서는 제외하였다.As a result of the peracetic acid content test after the purity test, our existing formulation and F002, F006 required an additional 4 days of aging time after reaction to satisfy the 6% content standard, F007 took 2 days, and F008 took 3 days. was identified as necessary (Table 1 and Figure 2). In the case of F003, F004, and F005, about 4 days were required for the purity suitability period, so they were excluded from the peracetic acid content test.
실험예 2. 과아세트산 6 %, 35 ℃ 공정Experimental Example 2. Peracetic acid 6%, 35 ℃ process
[표 2][Table 2]
35 ℃ 반응 조건에서, F008은 순도시험 품질기준을 만족시키기 위한 숙성시간이 최소 4 시간으로 단축되었으며, 과아세트산 6 % 함량 적합 기간은 3 시간으로 단축되었다 (표 2, 도 3 및 도 4). 즉, F008의 경우 과아세트산 합성에 추가적인 숙성은 요구되지 않았다. 상온 공정 보다 온도를 상승시켜 반응을 진행할 경우, 과아세트산 합성이 빠르게 됨을 확인 하였다.Under the reaction conditions of 35 ° C., the aging time for F008 to satisfy the purity test quality standard was reduced to at least 4 hours, and the suitable period for the 6% peracetic acid content was reduced to 3 hours (Table 2, FIGS. 3 and 4). That is, in the case of F008, additional aging was not required for peracetic acid synthesis. It was confirmed that when the reaction was carried out by raising the temperature rather than the room temperature process, the synthesis of peracetic acid was accelerated.
실험예 3. 과아세트산 6 %, 45 ℃ 공정Experimental Example 3. Peracetic acid 6%, 45 ℃ process
[표 3][Table 3]
45 ℃ 반응 조건에서, F006은 순도시험 품질기준을 만족시키기 위해 추가 숙성이 요구되지 않았으며, F007 및 F008은 단 2 시간의 추가 숙성시간만이 필요했다 (표 3 및 도 5). F006 내지 F008 모두 반응 시간 3 시간만으로 과아세트산 6 % 함량 적합 기준을 만족하고 추가적인 숙성 기간이 필요하지 않음을 확인하였다 (표 3 및 도 6).Under the reaction conditions of 45 ° C., F006 did not require additional aging to satisfy the purity test quality standards, and F007 and F008 required only 2 hours of additional aging time (Table 3 and FIG. 5). It was confirmed that all of F006 to F008 satisfied the suitability criterion for the 6% peracetic acid content with only a reaction time of 3 hours and did not require an additional aging period (Table 3 and FIG. 6).
위 결과를 종합하면, 본 발명자들은 pH 조절제 첨가 시 첨가하지 않은 경우에 비해 과아세트산 합성 기간을 단축시킬 수 있음을 확인하였으며, 특히 인산을 첨가한 경우에 비해 붕산 첨가시 반응시간이 획기적으로 단축되는 것을 확인하였다. 또한, 상온에서 반응시킨 것과 비교하여 높은 온도에서 과아세트산 합성 기간 및 과산화수소 순도 적합 기간이 단축되는 것을 확인하였다. Summarizing the above results, the present inventors confirmed that the addition of a pH adjuster can shorten the synthesis period of peracetic acid compared to when it is not added, and in particular, the reaction time is remarkably shortened when boric acid is added compared to when phosphoric acid is added confirmed that In addition, it was confirmed that the peracetic acid synthesis period and the hydrogen peroxide purity suitable period were shortened at a high temperature compared to the reaction at room temperature.
실험예 4. 침전물 형성 검토Experimental Example 4. Review of precipitate formation
본 발명의 과초산 용액은 인산을 촉매로 사용하는 기존 제제와 달리, 과초산 합성을 빠르게 하기 위하여 촉매로 붕산을 사용하고 있다. 상기 실시예 1 내지 3에서는 붕산 사용 시 과초산 합성 시간이 단축되는 것을 확인하였는데, 다음으로 실시예 4에서는 인산을 촉매로 사용하는 기존 제제에서 문제점으로 지적되었던 염 침전 현상이 붕산 사용으로 개선될 수 있는지 여부를 확인하고자 하였다. Unlike conventional formulations that use phosphoric acid as a catalyst, the peracetic acid solution of the present invention uses boric acid as a catalyst to speed up the synthesis of peracetic acid. In Examples 1 to 3, it was confirmed that the peracetic acid synthesis time was shortened when boric acid was used. Next, in Example 4, salt precipitation, which was pointed out as a problem in existing formulations using phosphoric acid as a catalyst, could be improved by using boric acid. I wanted to check whether there is.
일반적으로 수돗물의 칼슘이온 농도는 약 5 ppm 수준으로 알려져 있는데, 촉매제로 인산이 포함된 소독액을 좋은 품질의 정제수, 역삼투압수 이외에 수돗물 등 기준 미달의 용매에 희석하여 사용하면 인산염 축적이 발생하고, 다회 사용되는 기존 소독액은 칼슘이온과 반응한 침전물이 형성/축적되어 소독기에 문제를 일으켰다. In general, the concentration of calcium ions in tap water is known to be about 5 ppm. If a disinfectant solution containing phosphoric acid as a catalyst is diluted in a solvent that does not meet the standard such as tap water in addition to good quality purified water or reverse osmosis water, phosphate accumulation occurs, Existing disinfectant solutions used many times caused problems in the disinfector due to the formation/accumulation of precipitates that reacted with calcium ions.
붕산을 촉매로 사용한 본 발명의 제제의 염 형성을 평가하기 위해, 가혹조건으로 칼슘 이온을 약 10 배 수준 (55.49 ppm)으로 포함하는 물에 인산을 함유하는 기존 시판 제형 및 F002, 인산 대신 붕산을 함유하는 F006 및 F006-1을 각각 희석시키고 염이 형성되는 정도를 확인하였다. In order to evaluate the salt formation of the formulation of the present invention using boric acid as a catalyst, an existing commercial formulation containing phosphoric acid in water containing calcium ions at about 10 times the level (55.49 ppm) under harsh conditions and F002, boric acid instead of phosphoric acid The containing F006 and F006-1 were diluted, respectively, and the degree of salt formation was confirmed.
그 결과, 인산이 함유된 기존 시판 제형 및 F002에서는 칼슘염 침적물이 눈에 띄게 덩어리 형태로 형성되는 것을 확인할 수 있었다. 그러나, 붕산 촉매제를 포함하는 본 발명의 F006 및 F006-1 제제의 경우 기존 인산 함유 제제보다 칼슘염 형성이 눈에 띄게 억제되는 것을 확인할 수 있었다 (도 7). 이러한 결과는, 본 발명의 과아세트산 용액을 살균소독제로 사용할 경우 칼슘염 형성을 억제하고, 이에 따라 의료기기의 사용수명 연장 및 소독효과를 증대시킬 수 있음을 시사한다. As a result, it was confirmed that calcium salt deposits were conspicuously formed in the form of lumps in the existing commercial formulation and F002 containing phosphoric acid. However, in the case of the F006 and F006-1 formulations of the present invention containing the boric acid catalyst, it was confirmed that calcium salt formation was significantly inhibited compared to the conventional phosphoric acid-containing formulation (FIG. 7). These results suggest that when the peracetic acid solution of the present invention is used as a disinfectant, calcium salt formation can be suppressed, thereby extending the lifespan of medical devices and increasing the disinfection effect.
이상의 설명으로부터, 본 발명의 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention can be embodied in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the claims to be described later and equivalent concepts rather than the detailed description above are included in the scope of the present invention.
Claims (10)
(b) 상기 (a) 단계의 혼합물에 안정화제를 첨가하여 혼합하는 단계; 및
(c) 상기 (b) 단계의 혼합물에 붕산 0.5 중량% 내지 5 중량%를 혼합하고 30 ℃ 내지 50 ℃에서 2 시간 내지 4 시간 동안 반응시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법.
(a) mixing 37% to 41% by weight of acetic anhydride, 10% to 12% by weight of hydrogen peroxide and water;
(b) adding and mixing a stabilizer to the mixture of step (a); and
(c) Mixing 0.5% to 5% by weight of boric acid with the mixture of step (b) and reacting at 30 ° C. to 50 ° C. for 2 to 4 hours. Preparation of a peracetic acid solution provided as a single agent method.
(d) 상기 (c) 단계의 반응물을 상온에서 숙성시키는 단계를 포함하는, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 1,
(d) A method for producing a peracetic acid solution provided as a single agent, comprising the step of aging the reactant of step (c) at room temperature.
상기 숙성시키는 단계는 1 시간 내지 3 시간인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 1,
The aging step is 1 hour to 3 hours, a method for producing a peracetic acid solution provided as a single agent.
상기 (a) 단계의 아세트산 무수물은 39 중량%이고, 과산화수소수는 11.5 중량%이며,
상기 (c) 단계의 붕산은 2 중량%이고, 30 ℃ 내지 40 ℃에서 반응시키는 것인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 1,
The acetic anhydride in step (a) is 39% by weight, the hydrogen peroxide is 11.5% by weight,
The method for producing a peracetic acid solution provided as a single agent, wherein the boric acid in step (c) is 2% by weight and reacted at 30 ° C to 40 ° C.
상기 (a) 단계의 아세트산 무수물은 37 중량% 내지 41 중량%이고, 과산화수소수는 11.5 중량%이며,
상기 (c) 단계의 붕산은 2 중량%이고, 40 ℃ 내지 50 ℃에서 반응시키는 것인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 1,
The acetic anhydride in step (a) is 37% to 41% by weight, the hydrogen peroxide is 11.5% by weight,
The method for producing a peracetic acid solution provided as a single agent, wherein the boric acid in step (c) is 2% by weight and reacted at 40 ° C to 50 ° C.
상기 (b) 단계의 안정화제는 1-히드록시에탄-1,1-디포스폰산, 1-옥탄설폰산나트륨, {[(카르복시메틸)이미노]비스(에틸렌니트릴로)}테트라아세트산 및 EDTA 소듐염으로 이루어진 군에서 선택된 어느 하나 이상인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 1,
The stabilizer in step (b) is 1-hydroxyethane-1,1-diphosphonic acid, sodium 1-octanesulfonate, {[(carboxymethyl)imino]bis(ethylenenitrilo)}tetraacetic acid and EDTA A method for producing a peracetic acid solution provided as a single agent, which is at least one selected from the group consisting of sodium salts.
상기 안정화제는 0.1 중량% 내지 3 중량%인, 단일제로 제공되는 과아세트산 용액의 제조방법.
According to claim 6,
The stabilizer is 0.1% to 3% by weight, a method for producing a peracetic acid solution provided as a single agent.
A peracetic acid solution prepared by the method of any one of claims 1 to 7, provided as a single agent.
상기 과아세트산 용액은 과아세트산을 5.4 중량% 내지 8 중량%로 함유하는, 단일제로 제공되는 과아세트산 용액.
According to claim 8,
The peracetic acid solution provided as a single agent, containing 5.4% to 8% by weight of peracetic acid.
상기 과아세트산 용액은 과산화수소를 10 중량% 이하로 함유하는, 단일제로 제공되는 과아세트산 용액.According to claim 8,
The peracetic acid solution provided as a single agent, wherein the peracetic acid solution contains 10% by weight or less of hydrogen peroxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230057824A true KR20230057824A (en) | 2023-05-02 |
| KR102610645B1 KR102610645B1 (en) | 2023-12-06 |
Family
ID=86387915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210142044A KR102610645B1 (en) | 2021-10-22 | 2021-10-22 | A rapid preparation method for a peracetic acid solution provided as single formulation |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102610645B1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100363896B1 (en) | 2000-04-21 | 2002-12-16 | 이진식 | A medical instrument cleaning solution using peracetic acid and the manufacturing method of the above solution |
| KR100426937B1 (en) | 1998-10-19 | 2004-04-13 | 사라야 컴퍼니 리미티드 | Bactericidal/disinfectant peracetic acid composition |
| KR100597092B1 (en) * | 2005-01-27 | 2006-07-04 | 이승훈 | Aqueous solution of peracetic acid and method for producing the same |
| KR100876684B1 (en) | 2007-10-31 | 2009-01-07 | 이진식 | Preparation method of acidic antibiotic composition containing peracid and acetyl salicylic acid |
| US20100021558A1 (en) * | 2008-07-24 | 2010-01-28 | Fmc Corporation | Dilute Aqueous Peracid Solutions and Stabilization Method |
| CN101781241A (en) * | 2010-01-18 | 2010-07-21 | 江苏爱利思达清泉化学有限公司 | Preparation method of anhydrous peroxyacetic acid |
| CN102578144A (en) * | 2011-01-13 | 2012-07-18 | 北京康福乐科技有限公司 | Product and method for generating peracetic acid |
-
2021
- 2021-10-22 KR KR1020210142044A patent/KR102610645B1/en active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100426937B1 (en) | 1998-10-19 | 2004-04-13 | 사라야 컴퍼니 리미티드 | Bactericidal/disinfectant peracetic acid composition |
| KR100363896B1 (en) | 2000-04-21 | 2002-12-16 | 이진식 | A medical instrument cleaning solution using peracetic acid and the manufacturing method of the above solution |
| KR100597092B1 (en) * | 2005-01-27 | 2006-07-04 | 이승훈 | Aqueous solution of peracetic acid and method for producing the same |
| KR100876684B1 (en) | 2007-10-31 | 2009-01-07 | 이진식 | Preparation method of acidic antibiotic composition containing peracid and acetyl salicylic acid |
| US20100021558A1 (en) * | 2008-07-24 | 2010-01-28 | Fmc Corporation | Dilute Aqueous Peracid Solutions and Stabilization Method |
| CN101781241A (en) * | 2010-01-18 | 2010-07-21 | 江苏爱利思达清泉化学有限公司 | Preparation method of anhydrous peroxyacetic acid |
| CN102578144A (en) * | 2011-01-13 | 2012-07-18 | 北京康福乐科技有限公司 | Product and method for generating peracetic acid |
Non-Patent Citations (1)
| Title |
|---|
| Canadian Journal of Chemistry, Vol.41, 1963, pp.1826-1831* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102610645B1 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2843442B2 (en) | Compositions and methods of using them | |
| KR100597092B1 (en) | Aqueous solution of peracetic acid and method for producing the same | |
| JP4533618B2 (en) | Disinfectant cleaning composition | |
| CA1081079A (en) | Stable aqueous peroxy-containing concentrate | |
| JP2019073540A (en) | Method for producing aqueous solution containing chlorous acid to be used as disinfectant | |
| US20180360048A1 (en) | Stable compositions of uncomplexed iodine and methods of use | |
| CN104206413B (en) | A kind of thimerosal for haemodialysis control unit cleaning and sterilizing and preparation method thereof | |
| JP3219698B2 (en) | Manufacturing method of disinfectant solution | |
| US5962029A (en) | Iodine germicides that continuously generate free molecular iodine | |
| KR100876684B1 (en) | Preparation method of acidic antibiotic composition containing peracid and acetyl salicylic acid | |
| WO2004089089A1 (en) | Composition for bactericide production and process for producing organic peracid | |
| JP5332679B2 (en) | Peracetic acid aqueous solution with excellent stability | |
| WO1996012404A1 (en) | Antimicrobial agent containing quaternary ammonium salt | |
| CN113545363A (en) | Double-component chlorine dioxide disinfectant and preparation method and use method thereof | |
| JP2002249407A (en) | Sterilizing disinfectant | |
| KR20080098157A (en) | Sterilant.disinfectant composition comprising peracetic acid | |
| KR102610645B1 (en) | A rapid preparation method for a peracetic acid solution provided as single formulation | |
| JP2011502143A (en) | Bactericidal composition comprising peracid and acetylsalicylic acid | |
| KR102353182B1 (en) | Percitric acid aqueous solution and method for producing the same | |
| KR102307392B1 (en) | Peracetic acid disinfectant composition for medical devices with improved stability | |
| CN114747568A (en) | Medium-level disinfection wet tissue and preparation method thereof | |
| US5116623A (en) | Periodate iodophor composition with increased stability | |
| CN113749094B (en) | Peracetic acid disinfectant for endoscope and preparation method thereof | |
| KR100465046B1 (en) | A system of controlling microorganism containg hydrobromite of alkali metal or alkali earth metal and a control method using the same | |
| RU2195319C2 (en) | Disinfecting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |